Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Rejuveinix Reverses Severe Inflammatory Lung Damage in a Mouse Model of Fatal Sepsis

View ORCID ProfileFatih M. Uckun, View ORCID ProfileIbrahim H. Ozercan, Cemal Orhan, Marcus Gitterle, View ORCID ProfileKazim Sahin
doi: https://doi.org/10.1101/2020.12.31.424986
Fatih M. Uckun
1Drug Discovery Program, Reven Pharmaceuticals, Westminster, CO 80234, USA; ;
2Department of Developmental Therapeutics, Immunology, and Integrative Medicine, Ares Pharmaceuticals, St. Paul, MN 55110, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fatih M. Uckun
  • For correspondence: fatih.uckun@reven.com fatih.uckun@reven.com
Ibrahim H. Ozercan
3Department of Pathology Faculty of Medicine, Firat University, Elazig 23119, Turkey;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ibrahim H. Ozercan
  • For correspondence: ozercanih@firat.edu.tr
Cemal Orhan
4Department of Animal Nutrition, Faculty of Veterinary, Firat University, Elazig 23119, Turkey; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: corhan@firat.edu.tr ksahin@firat.edu.tr
Marcus Gitterle
5Department of Surgery, Christus Health System, Santa Rosa Hospital, New Braunfels, TX 78130, USA; ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: marcus.gitterle@christushealth.org
Kazim Sahin
4Department of Animal Nutrition, Faculty of Veterinary, Firat University, Elazig 23119, Turkey; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kazim Sahin
  • For correspondence: corhan@firat.edu.tr ksahin@firat.edu.tr
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Abstract

We set out to determine if our anti-sepsis drug candidate Rejuveinix (RJX) can effectively treat systemic inflammation in a mouse model of sepsis when used at a dose level that is >10-times lower than its maximum tolerated dose (MTD) for human subjects. Our findings obtained in the LPS-GalN mouse model of fatal sepsis provide experimental evidence that RJX exhibits potent single-agent anti-inflammatory activity and reverses very severe inflammatory lung injury when used therapeutically, thereby significantly improving the survival outcome. These findings demonstrate the clinical impact potential of RJX for the treatment of severe sepsis.

Competing Interest Statement

F.M.U. is an employee of Reven Pharmaceuticals, the sponsor for the clinical development of RJX. I.H.O, C.O., M.G., and K.S declare no current competing financial interests.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 02, 2021.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Rejuveinix Reverses Severe Inflammatory Lung Damage in a Mouse Model of Fatal Sepsis
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Rejuveinix Reverses Severe Inflammatory Lung Damage in a Mouse Model of Fatal Sepsis
Fatih M. Uckun, Ibrahim H. Ozercan, Cemal Orhan, Marcus Gitterle, Kazim Sahin
bioRxiv 2020.12.31.424986; doi: https://doi.org/10.1101/2020.12.31.424986
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Rejuveinix Reverses Severe Inflammatory Lung Damage in a Mouse Model of Fatal Sepsis
Fatih M. Uckun, Ibrahim H. Ozercan, Cemal Orhan, Marcus Gitterle, Kazim Sahin
bioRxiv 2020.12.31.424986; doi: https://doi.org/10.1101/2020.12.31.424986

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Toxicology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4384)
  • Biochemistry (9610)
  • Bioengineering (7104)
  • Bioinformatics (24897)
  • Biophysics (12632)
  • Cancer Biology (9974)
  • Cell Biology (14373)
  • Clinical Trials (138)
  • Developmental Biology (7966)
  • Ecology (12126)
  • Epidemiology (2067)
  • Evolutionary Biology (16002)
  • Genetics (10936)
  • Genomics (14756)
  • Immunology (9880)
  • Microbiology (23698)
  • Molecular Biology (9490)
  • Neuroscience (50925)
  • Paleontology (370)
  • Pathology (1541)
  • Pharmacology and Toxicology (2687)
  • Physiology (4023)
  • Plant Biology (8674)
  • Scientific Communication and Education (1512)
  • Synthetic Biology (2402)
  • Systems Biology (6444)
  • Zoology (1346)